Upsher-Smith Laboratories, Inc has entered into an exclusive agreement with Bluepharma S.A. to develop and distribute a generic product in a market category with U.S. sales greater than $75 million (IMS Health, 12 months ending in July 2016). This new collaboration underscores Upsher-Smith's commitment to expanding its strategic relationships and growing its generic product portfolio.
Under the terms of the agreement, Bluepharma will develop, manufacture and supply the product. Upsher-Smith will submit the Abbreviated New Drug Application (ANDA), and has exclusive rights to market and distribute the product in the United States as a generic under the Upsher-Smith label. Financial terms have not been disclosed.
"For years, Upsher-Smith has been a trusted partner in the U.S. generics marketplace," said Rusty Field, President, Upsher-Smith. "Upsher-Smith's consistent growth and success within this market can be attributed to our ability to build solid strategic relationships with leading pharmaceutical companies, like Bluepharma who share in our commitment to delivering quality, high-value generic products to patients."